# Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

> **NCT06686394** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 81 (estimated)

## Conditions studied

- Breast Neoplasms
- Breast Cancer

## Interventions

- **BIOLOGICAL:** Patritumab deruxtecan
- **BIOLOGICAL:** Trastuzumab
- **BIOLOGICAL:** Trastuzumab Biosimilar
- **BIOLOGICAL:** Pertuzumab
- **BIOLOGICAL:** Tucatinib

## Key facts

- **NCT ID:** NCT06686394
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-26
- **Primary completion:** 2030-04-18
- **Final completion:** 2030-04-18
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06686394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06686394, "Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06686394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*